Form D · Biotechnology
Omnipulse Biosciences, Inc.
Cambridge, MA · CIK 0001976713
Offering snapshot reported Jan 2, 2024 · SEC filing
- Reported sold
- $7M Offering amount: $12.5M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 15, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 2, 2024 | Initial | $6,999,999 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-501260
Source: Form D, filed Jan 2, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Joseph De Simone | Promoter |
| Robert Farra | Director, Executive |
| Felicia Hsu | Director |
| Ana Jacklenec | Director, Promoter |
| Robert Langer | Director, Promoter |
| David Zhu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
238 Main Street
Cambridge, MA, 02142
Cambridge, MA, 02142